Cytokine storm analysis agent

<!-- # COPYRIGHT NOTICE # This file is part of the "Universal Biomedical Skills" project. # Copyright (c) 2026 MD BABU MIA, PhD <[email protected]> # All Rights Reserved. # # This code is proprietary and confidential. # Unauthorized copying of this file, via any medium is strictly prohibited. # # Provenance: Authenticated by MD BABU MIA -->

---

name: 'cytokine-storm-analysis-agent' description: 'AI-powered cytokine release syndrome (CRS) and cytokine storm analysis for prediction, monitoring, and management in immunotherapy and infectious disease.' measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes. allowed-tools:

• read_file
• run_shell_command

---

Cytokine Storm Analysis Agent

The Cytokine Storm Analysis Agent provides comprehensive AI-driven analysis of cytokine release syndrome (CRS) and hyperinflammatory states. It integrates cytokine profiling, clinical parameters, and immunological markers for early prediction, severity grading, and treatment guidance in CAR-T therapy, sepsis, and viral infections.

When to Use This Skill

• When monitoring CAR-T patients for cytokine release syndrome risk.
• To predict CRS severity and timing post-immunotherapy.
• For analyzing cytokine panels in sepsis and viral infections (COVID-19).
• When guiding tocilizumab/siltuximab anti-IL-6 therapy decisions.
• To distinguish CRS from ICANS, HLH, and other inflammatory syndromes.

Core Capabilities

1. CRS Risk Prediction: ML models predict CRS development and severity from baseline factors (tumor burden, disease type, CAR-T product).

2. Real-Time Monitoring: Track cytokine dynamics (IL-6, IFN-γ, IL-10, ferritin) with early warning alerts.

3. Severity Grading: Automated ASTCT CRS grading using clinical parameters and biomarkers.

4. Differential Diagnosis: Distinguish CRS from HLH/MAS, ICANS, infection, and tumor lysis syndrome.

5. Treatment Guidance: AI-driven recommendations for tocilizumab, corticosteroids, and supportive care.

6. Outcome Prediction: Model response to anti-cytokine therapy and overall outcomes.

Cytokine Panel Analysis

Cytokine	Role in CRS	Kinetics	Therapeutic Target
IL-6	Central mediator	Early peak	Tocilizumab, Siltuximab
IFN-γ	T-cell activation	Early	Emapalumab
IL-1β	Inflammasome	Early	Anakinra
IL-10	Regulatory	Variable	-
TNF-α	Pro-inflammatory	Early	Infliximab (caution)
IL-2	T-cell expansion	Early	-
GM-CSF	Myeloid activation	Sustained	Lenzilumab

ASTCT CRS Grading (Automated)

Grade	Fever	Hypotension	Hypoxia
1	≥38°C	None	None
2	≥38°C	Responsive to fluids	Low-flow O2
3	≥38°C	One vasopressor	High-flow O2
4	≥38°C	Multiple vasopressors	Ventilation

Workflow

1. Input: Cytokine levels, vital signs, laboratory values, treatment history.

2. Risk Assessment: Baseline CRS risk stratification pre-therapy.

3. Monitoring: Real-time cytokine tracking with trend analysis.

4. Grading: Automated CRS grade assignment per ASTCT criteria.

5. Differential: Rule out mimics (infection, HLH, ICANS).

6. Treatment: Generate management recommendations.

7. Output: CRS risk score, grade, differential diagnosis, treatment plan.

Example Usage

User: "Monitor this CAR-T patient's cytokine levels and predict CRS severity."

Agent Action:

python3 Skills/Immunology_Vaccines/Cytokine_Storm_Analysis_Agent/crs_analyzer.py \
    --patient_data demographics.json \
    --cytokines cytokine_panel.csv \
    --vitals vital_signs.csv \
    --labs laboratory_values.csv \
    --cart_product tisagenlecleucel \
    --day_post_infusion 5 \
    --model crs_predictor_v3 \
    --output crs_report.json

AI/ML Models

CRS Risk Prediction:

• Features: tumor burden (LDH), lymphodepletion intensity, CAR-T dose, disease type
• Model: Gradient boosting with SHAP interpretability
• Performance: AUC 0.82-0.88 for severe CRS

Severity Trajectory:

• Time-series modeling of cytokine dynamics
• LSTM networks for temporal patterns
• Early warning 24-48 hours before clinical deterioration

Treatment Response:

• Tocilizumab response prediction
• Corticosteroid escalation timing
• ICU admission risk

Differential Diagnosis Decision Tree

Fever + Elevated Cytokines
          |
    CAR-T context?
    /           \
  Yes            No
   |              |
Hypotension?   Infection workup
   |              |
  CRS          Sepsis vs viral
   |
Neuro symptoms?
   |
  ICANS vs CRS
   |
Ferritin >10,000?
   |
  HLH/MAS evaluation

Clinical Decision Support

Tocilizumab Indication:

• Grade 2+ CRS
• Rapidly rising cytokines
• High-risk baseline features

Corticosteroid Indication:

• Tocilizumab-refractory CRS
• ICANS any grade
• Grade 3+ CRS

Prerequisites

• Python 3.10+
• scikit-learn, XGBoost for ML
• Time-series analysis libraries
• FHIR client for EHR integration

Related Skills

• CART_Design_Optimizer_Agent - For CAR-T design
• TCell_Exhaustion_Analysis_Agent - For T-cell function
• Clinical_NLP - For extracting symptoms from notes

Special Populations

1. Pediatric: Different baseline cytokine ranges
2. Post-COVID: Altered inflammatory responses
3. Bridging Therapy: Impact on CRS risk
4. Concurrent Infection: Confounding cytokine elevation

Author

AI Group - Biomedical AI Platform

<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->